Skip to main content
Contact Us
Subscribe
E-Edition
58°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Optinose Inc
(NQ:
OPTN
)
1.235
-0.015 (-1.20%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 8, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Optinose Inc
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE
December 06, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference
November 22, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Reports Third Quarter 2023 Financial Results and Operational Updates
November 09, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Announces Reporting Date for Third Quarter 2023 Financial Results
October 27, 2023
Conference Call and Webcast to be held November 9, 2023, at 8:00 a.m. Eastern Time
From
Optinose, Inc.
Via
GlobeNewswire
Optinose to Present at the 2023 Cantor Global Healthcare Conference
September 22, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Reports Second Quarter 2023 Financial Results and Operational Updates
August 10, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million
July 27, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 16, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Optinose to Present at the Jefferies Healthcare Conference
June 02, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Reports First Quarter 2023 Financial Results and Operational Updates
May 11, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE
May 04, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Announces Reporting Date for First Quarter 2023 Financial Results
May 01, 2023
Conference Call and Webcast to be held May 11, 2023, at 8:00 a.m. Eastern Time
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 18, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Optinose to Present at the Needham Virtual Healthcare Conference
April 12, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights
March 07, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Announces Reporting Date for Fourth Quarter 2022 Financial Results
February 28, 2023
Conference Call and Webcast to be held March 7, 2023 at 8:00 a.m. Eastern Time
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Submits Supplemental New Drug Application for XHANCE Label Expansion
February 21, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Announces CEO Transition and Business Update
January 31, 2023
Ramy Mahmoud, MD, MPH appointed CEO and to the Board of Directors
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Appoints Paul Spence as Chief Commercial Officer
December 15, 2022
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Announces Departure of Acting Chief Financial Officer
December 09, 2022
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Announces Corporate Updates and Presentation at the 34th Annual Piper Sandler Healthcare Conference
November 30, 2022
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Announces Pricing of Public Offering of Common Stock and Warrants
November 21, 2022
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Announces Proposed Public Offering of Common Stock and Warrants
November 21, 2022
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Reports Third Quarter 2022 Financial Results and Operational Updates
November 10, 2022
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Announces ReOpen2 Presentation at the American College of Asthma, Allergy, and Immunology (ACAAI) 2022 Annual Scientific Meeting
November 09, 2022
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Announces Reporting Date for Third Quarter 2022 Financial Results
November 07, 2022
Conference Call and Webcast to be held November 10, 2022, at 8:00 a.m. Eastern Time
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Announces Late Breaking Abstract Podium Presentation at IDWeek 2022
October 21, 2022
From
Optinose, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.